Future studies should include a correlation analysis of p53 isoform expression with response to in vivo differentiation therapy, as well as explore the potential of p53 isoform-targeted therapy in aggressive blood cancers like AML. This evidence concerns the gene TP53 and acute myeloid leukemia.